Elutia (ELUT) Competitors $1.74 -0.08 (-4.40%) As of 05/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. TRDA, OLMA, BNTC, ARCT, HRTX, SEPN, FULC, ATYR, ATAI, and ACBShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Fulcrum Therapeutics (FULC), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Entrada Therapeutics Olema Pharmaceuticals Benitec Biopharma Arcturus Therapeutics Heron Therapeutics Septerna Fulcrum Therapeutics Atyr PHARMA Atai Life Sciences Aurora Cannabis Entrada Therapeutics (NASDAQ:TRDA) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Is TRDA or ELUT more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Elutia's net margin of -218.72%. Entrada Therapeutics' return on equity of 16.11% beat Elutia's return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics25.53% 16.11% 10.39% Elutia -218.72%N/A -142.61% Which has higher valuation & earnings, TRDA or ELUT? Entrada Therapeutics has higher revenue and earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$172.22M1.69-$6.68M$0.819.49Elutia$23.71M2.99-$37.66M-$1.93-0.90 Does the MarketBeat Community believe in TRDA or ELUT? Entrada Therapeutics received 10 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 84.62% of users gave Entrada Therapeutics an outperform vote. CompanyUnderperformOutperformEntrada TherapeuticsOutperform Votes2284.62% Underperform Votes415.38%ElutiaOutperform Votes12100.00% Underperform VotesNo Votes Which has more risk and volatility, TRDA or ELUT? Entrada Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Does the media favor TRDA or ELUT? In the previous week, Entrada Therapeutics had 6 more articles in the media than Elutia. MarketBeat recorded 9 mentions for Entrada Therapeutics and 3 mentions for Elutia. Elutia's average media sentiment score of 1.09 beat Entrada Therapeutics' score of 0.61 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of TRDA or ELUT? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate TRDA or ELUT? Entrada Therapeutics presently has a consensus price target of $25.67, indicating a potential upside of 233.77%. Elutia has a consensus price target of $8.00, indicating a potential upside of 359.77%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEntrada Therapeutics beats Elutia on 13 of the 19 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.88M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.6730.5026.8419.71Price / Sales2.99400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book-1.053.286.794.50Net Income-$37.66M-$72.17M$3.23B$248.18M7 Day Performance1.16%4.28%4.07%1.14%1 Month Performance-24.35%7.62%12.52%15.20%1 Year Performance-49.12%-28.15%16.83%6.56% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.1654 of 5 stars$1.74-4.4%$8.00+359.8%-49.1%$70.88M$23.71M-0.67180Positive NewsTRDAEntrada Therapeutics2.947 of 5 stars$8.82+5.3%$25.67+191.0%-51.0%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2647 of 5 stars$4.76+3.5%$27.67+481.2%-46.5%$325.40MN/A-2.1770BNTCBenitec Biopharma2.4171 of 5 stars$13.14-3.6%$24.71+88.1%+42.3%$319.64M$80,000.00-8.7020News CoverageAnalyst ForecastAnalyst RevisionARCTArcturus Therapeutics2.9267 of 5 stars$11.59+5.6%$59.20+410.8%-59.3%$314.33M$138.39M-5.22180HRTXHeron Therapeutics3.8615 of 5 stars$2.05-2.8%$5.50+168.3%-45.3%$312.76M$148.52M-11.39300Positive NewsSEPNSepterna2.0583 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportAnalyst RevisionFULCFulcrum Therapeutics0.7844 of 5 stars$5.68+5.8%$8.63+51.8%-18.2%$306.60M$80M-18.32100ATYRAtyr PHARMA2.8106 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553Analyst ForecastATAIAtai Life Sciences2.3356 of 5 stars$1.44+3.6%$10.50+629.2%+13.7%$287.71M$308,000.00-1.7880News CoverageAnalyst ForecastGap DownACBAurora Cannabis0.6189 of 5 stars$5.06+4.3%N/A-26.8%$284.44M$320.81M101.221,340 Related Companies and Tools Related Companies TRDA Competitors OLMA Competitors BNTC Competitors ARCT Competitors HRTX Competitors SEPN Competitors FULC Competitors ATYR Competitors ATAI Competitors ACB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
